Hermann, Peter
Schmitz, Matthias
Cramm, Maria
Goebel, Stefan
Bunck, Timothy
Schütte-Schmidt, Julia
Schulz-Schaeffer, Walter
Stadelmann, Christine
Matschke, Jakob
Glatzel, Markus
Zerr, Inga
Funding for this research was provided by:
Robert-Koch-Institute (1369-341)
Georg-August-Universität Göttingen
Article History
Received: 25 November 2022
Revised: 22 December 2022
Accepted: 23 December 2022
First Online: 10 January 2023
Declarations
:
: The authors declare that they have no relevant financial or non-financial interests to disclose.
: The study was conducted according to the revised Declaration of Helsinki and Good Clinical Practice guidelines and has been approved by the local ethics committee in the University Medical Center, Göttingen (No. 11/11/93). Informed consent for scientific analyses was obtained from the patient or the legal next of kin in all autopsy-confirmed cases and all genetic prion diseases. Regarding other (anonymously presented) biomarker data, the registration and scientific evaluation of sCJD is considered a matter of public health in Germany. In this context, the CJD Surveillance group has been tasked with diagnostic and epidemiological research by the Robert-Koch Institute and the German Federal Ministry of Health.